騰盛博藥-B(02137.HK):獲得VIR-3434大中華區獨家開發和商業化權利
格隆匯7月4日丨騰盛博藥-B(02137.HK)發佈公吿,作為與Vir Biotechnology, Inc.(納斯達克股票代碼:VIR)更廣泛合作的一部分,公司行使了其選擇權,獲得VIR-3434在大中華區的獨家開發和商業化權利。這一舉措進一步增強了公司領先的乙型肝炎病毒(“HBV”)治療候選藥物臨牀管線,並作為公司致力於開發HBV功能性治癒療法的一部分,為公司探索潛在的聯合療法提供了更廣泛的選擇。
VIR-3434,亦稱為BRII-877,是一種靶向HBV的廣泛中和單克隆抗體,目前處於2期臨牀開發階段。這是公司對Vir傳染性疾病項目行使的第二項選擇權,且公司仍擁有其餘下兩項選擇權。
公司首席醫學官嚴立博士表示:“通過行使我們對VIR-3434(BRII-877)的選擇權,公司進一步鞏固了我們在為中國數千萬HBV患者開發功能性治癒療法方面的領先地位。Vir近期公佈的資料顯示,BRII-835(VIR-2218)和BRII-877(VIR-3434)有相互疊加作用,可顯著降低乙型肝炎表面抗原(“HBsAg”),無顯著的臨牀安全信號。我們相信,這一新項目將進一步加強我們的HBV管線,為所有患者提供更有效、更有保證的HBsAg降低方案。BRII-877(VIR-3434)將融入到我們的創新藥物聯合療法策略中,從而提高在所有患者人羣的功能性治癒率。公司一直致力於探索一系列的聯合治療方案,我們與Vir的持續戰略合作伙伴關係,以及持續擴展我們強大的HBV管線等舉措,將進一步加強我們對HBV患者的承諾。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.